List view / Grid view
12 December 2016 | By Niamh Louise Marriott, Digital Editor
It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The visibility of DC Bead Lumi helps optimise patient treatment by enabling real-time confirmation of bead location during the embolization procedure...
9 December 2016 | By Niamh Louise Marriott, Digital Editor
Pharma Giant Pfizer has been fined a record £84.2 million after it broke competition law by charging excessive and unfair prices to the UK...
8 December 2016 | By Dolomite Bio
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer...
7 December 2016 | By Almac Group
Offers clients advanced, best-in-class eClinical technology solutions...
6 December 2016 | By Glass Solutions
Glass Solutions is the supplier of choice for a wide variety of laboratories, providing specialist scientific glassware backed by unrivaled service and support...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
The new technology makes sure the privacy of genomic information is not compromised as patients’ data go through various processing steps...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
The updated US label for Veltassa recommends patients take Veltassa at least 3 hours before or 3 hours after other oral medications...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
All employees of PII will join Perigord, with the combination expected to deliver the most robust menu of labelling and labelling-related services...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
The XEN Glaucoma Treatment System reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas...
